Skip to main content

Celltrion Pharm, Inc. (068760.KQ)

KOE Healthcare Drug Manufacturers - Specialty & GenericView data quality →
49.6Fair

ValueMarkers Composite Index

Top 27%#32,601 of 44,714
Overvalued

287% above intrinsic value ($10)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.69
Low Risk
Altman
6.16
Safe
DCF Value
$10
Overvalued
ROIC
7.0%
Low
P/E
63.2
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Celltrion Pharm, Inc. (068760.KQ) — VMCI valuation read

The headline on Celltrion Pharm, Inc. (068760.KQ) is a 50/100 VMCI score, set against a Healthcare sector median of 50. That 0-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

068760.KQ insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** 068760.KQ trades at 23.0x earnings, 28% above the Healthcare median of 18.0x sets the value side. ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 0.5x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on 068760.KQ.

068760.KQ fell 2.2% over the trailing 7 days, with a -14.3% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 068760.KQ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.